Top

Published in:

01-12-2020 | Obesity | Original investigation

Hospitalization for heart failure incidence according to the transition in metabolic health and obesity status: a nationwide population-based study

Authors: You-Bin Lee, Da Hye Kim, Seon Mee Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Yong Gyu Park, Kyungdo Han, Hye Jin Yoo

Published in: Cardiovascular Diabetology | Issue 1/2020

Abstract

Background

We aimed to investigate the hazard of hospitalization for heart failure (hHF) according to the transitions in metabolic health and obesity status.

Methods

The Korean National Health Insurance Service datasets from 2002 to 2017 were used for this nationwide, longitudinal, population-based study. The hazard of hHF was analyzed according to the eight groups stratified by stability in metabolic health and transition in obesity status among initially metabolically healthy adults who underwent two cycles of health examinations in 2009–2010 and 2013–2014 (N = 7,148,763).

Results

During two examinations, 48.43% of the initially metabolically healthy obese (MHO) individuals and 20.94% of the initially metabolically healthy non-obese (MHNO) individuals showed changes in their metabolic health and obesity status. During a mean follow-up of 3.70 years, 3151 individuals were hospitalized for HF. When stable MHNO individuals were set as the reference, transition to metabolically unhealthy phenotype was associated with an increased hazard of hHF; the hazard ratio (HR) and 95% confidence interval (CI) in the individuals who transformed from MHO to metabolically unhealthy non-obese was 2.033 (1.579–2.616). The constant MHO group had a 17.3% increased hazard of hHF compared with the stable MHNO group [HR (95% CI) 1.173 (1.039–1.325)]. Individuals who shifted from MHO to MHNO showed a 34.3% lower hazard of hHF compared with those who maintained the MHO category [HR (95% CI) 0.657 (0.508–0.849)].

Conclusion

Dynamic changes in metabolic health and obesity status were observed during a relatively short interval of 3–5 years. Loss of metabolic health was significantly associated with an increased hazard of hHF. Even if metabolic health was maintained, persistent obesity remained as a risk factor for hHF, and transition from MHO to MHNO had a protective effect against hHF. Therefore, the prevention and control of obesity while maintaining metabolic health would be crucial in preventing hHF.

Available only for authorised users

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239. https://doi.org/10.1016/j.jacc.2013.05.019.CrossRefPubMed

Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the american heart association. Circulation. 2019;139(10):e56–528. https://doi.org/10.1161/CIR.0000000000000659.CrossRefPubMed

Kosiborod MN, Jhund P, Docherty KF, Diez M, Petrie MC, Verma S, et al. Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation. 2019. https://doi.org/10.1161/circulationaha.119.044138.CrossRefPubMedPubMedCentral

Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30–41. https://doi.org/10.1038/nrcardio.2010.165.CrossRefPubMed

Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305–13. https://doi.org/10.1056/NEJMoa020245.CrossRefPubMed

Carbone S, Lavie CJ, Arena R. Obesity and heart failure: focus on the obesity paradox. Mayo Clin Proc. 2017;92(2):266–79. https://doi.org/10.1016/j.mayocp.2016.11.001.CrossRefPubMed

Horwich TB, Fonarow GC, Clark AL. Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis. 2018;61(2):151–6. https://doi.org/10.1016/j.pcad.2018.05.005.CrossRefPubMed

Chrysant SG, Chrysant GS. The single use of body mass index for the obesity paradox is misleading and should be used in conjunction with other obesity indices. Postgrad Med. 2019;131(2):96–102. https://doi.org/10.1080/00325481.2019.1568019.CrossRefPubMed

Rhee EJ. Being metabolically healthy, the most responsible factor for vascular health. Diabetes Metab J. 2018;42(1):19–25. https://doi.org/10.4093/dmj.2018.42.1.19.CrossRefPubMedPubMedCentral

10.

Mongraw-Chaffin M, Foster MC, Anderson CAM, Burke GL, Haq N, Kalyani RR, et al. Metabolically healthy obesity, transition to metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2018;71(17):1857–65. https://doi.org/10.1016/j.jacc.2018.02.055.CrossRefPubMedPubMedCentral

11.

Kouvari M, Panagiotakos DB, Yannakoulia M, Georgousopoulou E, Critselis E, Chrysohoou C, et al. Transition from metabolically benign to metabolically unhealthy obesity and 10-year cardiovascular disease incidence: the ATTICA cohort study. Metabolism. 2019;93:18–24. https://doi.org/10.1016/j.metabol.2019.01.003.CrossRefPubMed

12.

Caleyachetty R, Thomas GN, Toulis KA, Mohammed N, Gokhale KM, Balachandran K, et al. Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. J Am Coll Cardiol. 2017;70(12):1429–37. https://doi.org/10.1016/j.jacc.2017.07.763.CrossRefPubMed

13.

Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(5):525–38. https://doi.org/10.1016/j.jacc.2019.11.044.CrossRefPubMedPubMedCentral

14.

Voulgari C, Tentolouris N, Dilaveris P, Tousoulis D, Katsilambros N, Stefanadis C. Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals. J Am Coll Cardiol. 2011;58(13):1343–50. https://doi.org/10.1016/j.jacc.2011.04.047.CrossRefPubMed

15.

Echouffo-Tcheugui JB, Short MI, Xanthakis V, Field P, Sponholtz TR, Larson MG, et al. Natural history of obesity subphenotypes: dynamic changes over two decades and prognosis in the Framingham heart study. J Clin Endocrinol Metab. 2019;104(3):738–52. https://doi.org/10.1210/jc.2018-01321.CrossRefPubMed

16.

Cho YK, Kang YM, Yoo JH, Lee J, Park JY, Lee WJ, et al. Implications of the dynamic nature of metabolic health status and obesity on risk of incident cardiovascular events and mortality: a nationwide population-based cohort study. Metabolism. 2019;97:50–6. https://doi.org/10.1016/j.metabol.2019.05.002.CrossRefPubMed

17.

Eckel N, Li Y, Kuxhaus O, Stefan N, Hu FB, Schulze MB. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses’ Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol. 2018;6(9):714–24. https://doi.org/10.1016/s2213-8587(18)30137-2.CrossRefPubMed

18.

Soriguer F, Gutierrez-Repiso C, Rubio-Martin E, Garcia-Fuentes E, Almaraz MC, Colomo N, et al. Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. J Clin Endocrinol Metab. 2013;98(6):2318–25. https://doi.org/10.1210/jc.2012-4253.CrossRefPubMed

19.

Huh JH, Ahn SG, Kim YI, Go T, Sung K-C, Choi JH, et al. Impact of longitudinal changes in metabolic syndrome status over 2 years on 10-year incident diabetes mellitus. Diabetes Metab J. 2019;43(4):530–8.CrossRefPubMedPubMedCentral

20.

Lee YH, Han K, Ko SH, Ko KS, Lee KU. Data analytic process of a nationwide population-based study using national health information database established by national health insurance service. Diabetes Metab J. 2016;40(1):79–82. https://doi.org/10.4093/dmj.2016.40.1.79.CrossRefPubMedPubMedCentral

21.

Cheol Seong S, Kim YY, Khang YH, Heon Park J, Kang HJ, Lee H, et al. Data resource profile: the national health information database of the national health insurance service in South Korea. Int J Epidemiol. 2017;46(3):799–800. https://doi.org/10.1093/ije/dyw253.CrossRefPubMed

22.

Lee Y-B, Han K, Kim B, Jin S-M, Lee S-E, Jun JE, et al. High proportion of adult cases and prevalence of metabolic syndrome in type 1 diabetes mellitus population in Korea: a Nationwide Study. Diabetes Metab J. 2019;43(1):76–89.CrossRefPubMed

23.

Lee YB, Han K, Kim B, Lee SE, Jun JE, Ahn J, et al. Risk of early mortality and cardiovascular disease in type 1 diabetes: a comparison with type 2 diabetes, a nationwide study. Cardiovasc Diabetol. 2019;18(1):157. https://doi.org/10.1186/s12933-019-0953-7.CrossRefPubMedPubMedCentral

24.

Yun JS, Park YM, Han K, Cha SA, Ahn YB, Ko SH. Severe hypoglycemia and the risk of cardiovascular disease and mortality in type 2 diabetes: a nationwide population-based cohort study. Cardiovasc Diabetol. 2019;18(1):103. https://doi.org/10.1186/s12933-019-0909-y.CrossRefPubMedPubMedCentral

25.

Lee J, Hur H, Lee JW, Youn HJ, Han K, Kim NW, et al. Long-term risk of congestive heart failure in younger breast cancer survivors: a nationwide study by the SMARTSHIP group. Cancer. 2020;126(1):181–8. https://doi.org/10.1002/cncr.32485.CrossRefPubMed

26.

Kim MK, Lee WY, Kang JH, Kang JH, Kim BT, Kim SM, et al. 2014 clinical practice guidelines for overweight and obesity in Korea. Endocrinol Metab (Seoul). 2014;29(4):405–9. https://doi.org/10.3803/EnM.2014.29.4.405.CrossRefPubMedPubMedCentral

27.

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120(16):1640–5. https://doi.org/10.1161/circulationaha.109.192644.CrossRefPubMed

28.

Lee S, Park HS, Kim SM, Kwon HS, Kim DY, Kim DJ, et al. Cut-off points of waist circumference for defining abdominal obesity in the Korean population. J Obes Metabol Syndr. 2006;15(1):1–9.

29.

Goel S, Sharma A, Garg A. Effect of alcohol consumption on cardiovascular health. Curr Cardiol Rep. 2018;20(4):19. https://doi.org/10.1007/s11886-018-0962-2.CrossRefPubMed

30.

Lemstra M, Rogers M, Moraros J. Income and heart disease: neglected risk factor. Can Fam Physician. 2015;61(8):698–704.PubMedPubMedCentral

31.

Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease: a systematic integrative review. Biomed Res Int. 2014;2014:937398. https://doi.org/10.1155/2014/937398.CrossRefPubMedPubMedCentral

32.

Kim MK, Han K, Kim HS, Park YM, Kwon HS, Yoon KH, et al. Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study. Eur Heart J. 2017;38(48):3560–6. https://doi.org/10.1093/eurheartj/ehx585.CrossRefPubMedPubMedCentral

33.

Nalliah CJ, Sanders P, Kottkamp H, Kalman JM. The role of obesity in atrial fibrillation. Eur Heart J. 2016;37(20):1565–72. https://doi.org/10.1093/eurheartj/ehv486.CrossRefPubMed

34.

Selvaraj S, Martinez EE, Aguilar FG, Kim KY, Peng J, Sha J, et al. Association of central adiposity with adverse cardiac mechanics: findings from the hypertension genetic epidemiology network study. Circ Cardiovasc Imaging. 2016;9:6. https://doi.org/10.1161/circimaging.115.004396.CrossRef

35.

Lee H, Choi EK, Lee SH, Han KD, Rhee TM, Park CS, et al. Atrial fibrillation risk in metabolically healthy obesity: a nationwide population-based study. Int J Cardiol. 2017;240:221–7. https://doi.org/10.1016/j.ijcard.2017.03.103.CrossRefPubMed

36.

Kim YG, Han KD, Choi JI, Boo KY, Kim DY, Oh SK, et al. The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study. Cardiovasc Diabetol. 2019;18(1):128. https://doi.org/10.1186/s12933-019-0932-z.CrossRefPubMedPubMedCentral

37.

Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015;12(4):230–43. https://doi.org/10.1038/nrcardio.2015.2.CrossRefPubMed

38.

Neeland IJ, Poirier P, Despres JP. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation. 2018;137(13):1391–406. https://doi.org/10.1161/circulationaha.117.029617.CrossRefPubMedPubMedCentral

39.

Ingelsson E, Arnlov J, Lind L, Sundstrom J. Metabolic syndrome and risk for heart failure in middle-aged men. Heart. 2006;92(10):1409–13. https://doi.org/10.1136/hrt.2006.089011.CrossRefPubMedPubMedCentral

40.

Arcopinto M, Schiavo A, Salzano A, Bossone E, D’Assante R, Marsico F, et al. Metabolic syndrome in heart failure: friend or foe? Heart Fail Clin. 2019;15(3):349–58. https://doi.org/10.1016/j.hfc.2019.02.004.CrossRefPubMed

41.

Neeland IJ, Gupta S, Ayers CR, Turer AT, Rame JE, Das SR, et al. Relation of regional fat distribution to left ventricular structure and function. Circ Cardiovasc Imag. 2013;6(5):800–7. https://doi.org/10.1161/CIRCIMAGING.113.000532.CrossRef

42.

Abbasi SA, Hundley WG, Bluemke DA, Jerosch-Herold M, Blankstein R, Petersen SE, et al. Visceral adiposity and left ventricular remodeling: the multi-ethnic study of atherosclerosis. Nutr Metab Cardiovasc Dis. 2015;25(7):667–76. https://doi.org/10.1016/j.numecd.2015.03.016.CrossRefPubMedPubMedCentral

43.

Rozenbaum Z, Topilsky Y, Khoury S, Pereg D, Laufer-Perl M. Association of body mass index and diastolic function in metabolically healthy obese with preserved ejection fraction. Int J Cardiol. 2019;277:147–52. https://doi.org/10.1016/j.ijcard.2018.08.008.CrossRefPubMed

44.

Morkedal B, Vatten LJ, Romundstad PR, Laugsand LE, Janszky I. Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trondelag Health Study), Norway. J Am Coll Cardiol. 2014;63(11):1071–8. https://doi.org/10.1016/j.jacc.2013.11.035.CrossRefPubMed

45.

Sundström J, Bruze G, Ottosson J, Marcus C, Näslund I, Neovius M. Weight loss and heart failure. Circulation. 2017;135(17):1577–85. https://doi.org/10.1161/CIRCULATIONAHA.116.025629.CrossRefPubMedPubMedCentral

46.

Nguyen NT, Varela JE. Bariatric surgery for obesity and metabolic disorders: state of the art. Nat Rev Gastroenterol Hepatol. 2017;14(3):160–9. https://doi.org/10.1038/nrgastro.2016.170.CrossRefPubMed

47.

Pontiroli AE, Zakaria AS, Fanchini M, Osio C, Tagliabue E, Micheletto G, et al. A 23-year study of mortality and development of co-morbidities in patients with obesity undergoing bariatric surgery (laparoscopic gastric banding) in comparison with medical treatment of obesity. Cardiovasc Diabetol. 2018;17(1):161. https://doi.org/10.1186/s12933-018-0801-1.CrossRefPubMedPubMedCentral

48.

Xu L, Ota T. Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: focus on fat browning and macrophage polarization. Adipocyte. 2018;7(2):121–8. https://doi.org/10.1080/21623945.2017.1413516.CrossRefPubMedPubMedCentral

49.

Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, et al. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: a prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study). Diabetes Obes Metab. 2019;21(8):1990–5. https://doi.org/10.1111/dom.13750.CrossRefPubMedPubMedCentral

50.

Isaacs D, Prasad-Reddy L, Srivastava SB. Role of glucagon-like peptide 1 receptor agonists in management of obesity. Am J Health Syst Pharm. 2016;73(19):1493–507. https://doi.org/10.2146/ajhp150990.CrossRefPubMed

51.

Sposito AC, Berwanger O, de Carvalho LSF, Saraiva JFK. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 2018;17(1):157. https://doi.org/10.1186/s12933-018-0800-2.CrossRefPubMedPubMedCentral

52.

Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241(19):2035–8. https://doi.org/10.1001/jama.241.19.2035.CrossRefPubMed

53.

Rosengren A, Edqvist J, Rawshani A, Sattar N, Franzén S, Adiels M, et al. Excess risk of hospitalisation for heart failure among people with type 2 diabetes. Diabetologia. 2018;61(11):2300–9. https://doi.org/10.1007/s00125-018-4700-5.CrossRefPubMedPubMedCentral

54.

Oluwagbemigun K, Buyken AE, Alexy U, Schmid M, Herder C, Nothlings U. Developmental trajectories of body mass index from childhood into late adolescence and subsequent late adolescence-young adulthood cardiometabolic risk markers. Cardiovasc Diabetol. 2019;18(1):9. https://doi.org/10.1186/s12933-019-0813-5.CrossRefPubMedPubMedCentral

55.

Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heymsfield SB. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol. 1996;143(3):228–39. https://doi.org/10.1093/oxfordjournals.aje.a008733.CrossRefPubMed

56.

Camhi SM, Bray GA, Bouchard C, Greenway FL, Johnson WD, Newton RL, et al. The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences. Obesity (Silver Spring). 2011;19(2):402–8. https://doi.org/10.1038/oby.2010.248.CrossRef

57.

Despres JP, Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the health, risk factors, exercise training, and genetics (HERITAGE) family study. Arterioscler Thromb Vasc Biol. 2000;20(8):1932–8. https://doi.org/10.1161/01.atv.20.8.1932.CrossRefPubMed

58.

Savji N, Meijers WC, Bartz TM, Bhambhani V, Cushman M, Nayor M, et al. The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. JACC Heart Fail. 2018;6(8):701–9. https://doi.org/10.1016/j.jchf.2018.05.018.CrossRefPubMedPubMedCentral

Title: Hospitalization for heart failure incidence according to the transition in metabolic health and obesity status: a nationwide population-based study
Authors: You-Bin Lee
Da Hye Kim
Seon Mee Kim
Nan Hee Kim
Kyung Mook Choi
Sei Hyun Baik
Yong Gyu Park
Kyungdo Han
Hye Jin Yoo
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Obesity
Obesity
Heart Failure
Published in: Cardiovascular Diabetology / Issue 1/2020
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/s12933-020-01051-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial

High triglyceride-glucose index is associated with subclinical cerebral small vessel disease in a healthy population: a cross-sectional study

Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis

Glucose variability and the risks of stroke, myocardial infarction, and all-cause mortality in individuals with diabetes: retrospective cohort study

Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk

Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials